Literature DB >> 18277019

Nutritional and prognostic significance of sick euthyroid syndrome in non-small cell lung cancer patients.

Seyhan Ekrem Cengiz1, Erdogan Cetinkaya, Sedat Altin, Zeki Gunluoglu, Adalet Demir, Gulsah Gunluoglu, Kursat Epozturk.   

Abstract

OBJECTIVES: Our study aimed to determine the frequency of sick euthyroid syndrome (SES) among patients diagnosed as non-small cell lung cancer (NSCLC) and its association with the stage of the disease, Karnofsky index (KI), and nutritional parameters.
METHODS: We enrolled 80 consecutive patients with newly diagnosed NSCLC. Cases with NSCLC were staged by using the TNM system. The cases were examined for thyroid function tests, KI and nutritional evaluation before treatment. Moreover, cases were investigated for their overall survival ratio.
RESULTS: Out of 80 patients, SES was identified in 28 (35%). SES was more frequent among stage III (26%) and stage IV (62%) cases. The body mass index (BMI), KI and serum albumin level were found to be significantly low in cases with SES when compared to cases without SES. SES was found to be negatively correlated with BMI, KI and serum albumin level, and it was positively correlated with disease stage and weight loss. Additionally, the presence of SES was found as a prognostic factor at survival analysis (p=0.0002).
CONCLUSION: SES was frequently seen in cases with NSCLC. SES can be used as a predictor of poor prognosis in NSCLC patients.

Entities:  

Mesh:

Year:  2008        PMID: 18277019     DOI: 10.2169/internalmedicine.47.0423

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  8 in total

Review 1.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

Review 2.  Thyroid Allostasis-Adaptive Responses of Thyrotropic Feedback Control to Conditions of Strain, Stress, and Developmental Programming.

Authors:  Apostolos Chatzitomaris; Rudolf Hoermann; John E Midgley; Steffen Hering; Aline Urban; Barbara Dietrich; Assjana Abood; Harald H Klein; Johannes W Dietrich
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-20       Impact factor: 5.555

3.  Sick Euthyroid Syndrome on Presentation of Patients With COVID-19: A Potential Marker for Disease Severity.

Authors:  Yair Schwarz; Ruth Percik; Bernice Oberman; Dana Yaffe; Eyal Zimlichman; Amir Tirosh
Journal:  Endocr Pract       Date:  2021-01-11       Impact factor: 3.443

Review 4.  The Intriguing Thyroid Hormones-Lung Cancer Association as Exemplification of the Thyroid Hormones-Cancer Association: Three Decades of Evolving Research.

Authors:  Maria V Deligiorgi; Dimitrios T Trafalis
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

5.  Prognostic nutrition index is associated with the all-cause mortality in sepsis patients: A retrospective cohort study.

Authors:  He Wu; Chongjun Zhou; Wanquan Kong; Yi Zhang; Da Pan
Journal:  J Clin Lab Anal       Date:  2022-02-20       Impact factor: 2.352

6.  [Comparison of the changes of thyroid hormones after video-assisted thoracoscopic surgery and conventional thoracotomy in patients with non-small cell lung cancer].

Authors:  Wenxin Tian; Hongfeng Tong; Yaoguang Sun; Xin Li; Qingjun Wu; Chao Ma; Peng Jiao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-12

7.  Prevalence and Related Factors of Euthyroid Sick Syndrome in Children with Untreated Cancer According to Two Different Criteria

Authors:  Ali Duyu; Elvan Cağlar Çıtak; Erdem Ak; Serhan Küpeli; Begül Yağcı Küpeli; İbrahim Bayram; Gülay Sezgin; Gülçin Eskendari; Kerem Sezer
Journal:  J Clin Res Pediatr Endocrinol       Date:  2018-03-19

8.  Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.

Authors:  Tomoko Yamamoto Funazo; Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Yuto Yasuda; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Toyohiro Hirai; Young Hak Kim
Journal:  Sci Rep       Date:  2019-11-19       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.